Evaluation of some Virulence Factors and Drug Resistance of Bacteria Isolated from the Urine of Patients with TCC-Bladder Cancer

Sura Mouaid Abbas* Maysaa Abdul Razzaq Dhahi

Microbiology Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq.
*Corresponding author: sursbio@gmail.com, dr_maysaa@yahoo.com
*ORCID ID: https://orcid.org/0000-0001-5132-0504, https://orcid.org/0000-0003-3436-8084

Received 17/11/2020, Accepted 3/3/2021, Published Online First 20/11/2021, Published 1/6/2022

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract: Urinary tract infections (UTIs) mean microbial pathogens in the urethra or bladder (lower urinary tract). Important risk factors for recurrent UTI include obstruction of the urinary tract, use of a bladder catheter or a suppressed immune system. This study aims to isolate and identify bacteria from patients with TCC-bladder cancer or patients with a negative cystoscope and estimate antibiotic susceptibility patterns and evaluate some of the virulence factors. From a total of 62 patients with TCC-BC or negative cystoscope, only 35 favorable bacterial growths were obtained, including Escherichia coli (UPEC), a significant bacterial isolate, and Stenotrophomonas maltophilia. The percentage of multi drug-resistance bacteria (MDR) was identified in (62.8%) while the extended drug-resistance bacteria (XDR) was (28.5%). All isolates were producer for biofilm either moderately 18/35 (49%) or strongly 18/35 (51%). Only 25/35 (71%) isolates were produced for siderophore, while 10/35 (29%) isolates were non-produced. Inducing cytochrome P450 expression protein was seen in (14/35) 40% isolates. In conclusion, patients with TCC-BC or negative cystoscope who had a urinary catheter or immune-compromised were at high risk of infecting with nosocomial or opportunistic pathogens, which could be develop antibiotic resistance, the central problem in the cohort of patients undergoing chemotherapy or immune cancer therapy.

Key words: Antibiotic susceptibility, CytochromeP450, Siderophore production, TCC-BC, Virulence factors.

Introduction: Urinary tract infections (UTIs) mean microbial pathogens in the urethra or bladder (lower urinary tract), or ureter and pelvis of the kidney (upper urinary tract). In men, the prostate also may be involved. Risk factors for recurrent UTI include obstruction of the urinary tract, use of a bladder catheter, a suppressed immune system, estrogen deficiency, genetic predisposition, and sexual intercourse. Uropathogenic E. coli (UPEC) can invade bladder epithelial cells during UTI and form intracellular bacterial communities (IBC), which can be the cause of UTI recurrence.

Uropathogens bacterial have several virulence determinants necessary for initial adhesion and colonization of host mucosal surfaces, cell and tissue invasion, overcoming the host defense mechanisms, and causing persistent and chronic infections. These microbial virulence determinants include surface factors (fimbriae, adhesins, P pili and type-1 pili) and extracellular factors (toxins, siderophores, enzymes, and biofilm formation). Transient inflammation is considered part of the body's immune defense against pathogens, while persistent inflammation may promote cancer development. This study was aimed to isolate and identify bacteria from urine samples obtained from patients with transitional cell carcinoma-bladder cancer and patients with negative cystoscope and to detect antibiotic
susceptibility patterns. Also, to evaluate some virulence factors in isolated bacteria.

Materials and Methods:
Methodology
Patients and sampling
In the present study, 62 urine samples were collected from patients with TCC—BC, and patients with negative cystoscope (as negative control for TCC-BC) from AL-Imamein AL-Kadhmain Medical City Hospital and Ghazi-AL-Hariri Specialized Surgery Hospital/ Medical City Hospital, Baghdad Iraq, in period extended for 10 months. These samples (50 from male and 10 from female) were cultured on MacConkey agar, nutrient agar, blood agar, and UTI medium for bacterial growth (incubated at 37°C for 24 hrs).

Identification of bacteria using VITEK 2 compact system
Bacteria were subjected for identification by VITEK 2 compact system according to the instruction provided by the company. The turbidity was adjusted to 0.5 MacFarland turbidity range and measured using visible spectrophotometer DensiChekTM Plus. The bacterial suspension was used to inoculate the VITEK 2 system (bioMérieux/France). Interpretation of results was performed according to VITEK 2 compact system special software to identify bacterial species and strains.

Determination of antibiotic susceptibility using VITEK® 2 compact
Susceptibility to the following antimicrobial agents (depending on the bacterial genus) was determined using VITEK 2 compact system: antibiotic included: Ticarcillin, Ticarcillin/ clavulanic acid, Piperacillin, Piperacillin/Tazobactam, Imipenem, Meropenem, Amikacin, Trimethoprim/sulfamethoxazole, Gentamicin, Tobramycin, Ciprofloxacin, Ceftazidime, Minocycline, Cefepime, Azteronam, Colistin, Trimethoprim, GN.H.L.S Gentamicin High Level (synergy), Streptomycin High Level (synergy), linezolid, tetracycline, Erythromycin, Tigecycline, Levofloxacin, Vancomycin, Teicoplanin, Benzylpenicillin, Oxacillin, Clindamycin, Fusidic acid, Moxifloxacin and Rifampicin. The break point for each antimicrobial used was determined according to CLSI (2019) 6.

Identification of uropathic E.coli by detection of pap E using Conventional PCR
Uropathogenic E.coli was identified by detection of pap E using conventional PCR. Extraction of DNA was done using XIT™ Genomic DNA Purification Kit following manufacturer instructions. PCR was performed using a specific primer set for the detection of pap E in bacterial extracted DNA. PCR products were electrophoresed in 1.5% agarose gel. The appearance of a band with a molecular size 321 bp referred to the amplification of papE.

Biofilm assay using Tissue culture plate method
Overnight Bacterial growth was grown on LB broth at 37 °C for 24hr. The culture was adjusted to 0.01 with McFarland solution. Of bacterial growth,50µl was added to 150 µl of LB broth on tissue culture plate wells and incubated at 37 °C for 24 hrs. The culture was removed carefully, and wells were washed two times with 250 µl distilled water. Then, 250 µl of (0.2%) of Crystal violet was added and incubated for 10 minutes at 25 ºC. Wells were washed with distilled water 2-3 times and dried at room temperature. Finally, 200 µl of 95% ethanol was added to wells. Optical density (O.D) was measured at 630 nm. Interpretation producer of results was done 8.

Siderophore Production
Siderophore production using M9 medium supplemented with glucose 20% and casmino acid 20% was prepared 9. Bacterial growth turbidity was adjusted to 0.01 with McFarland solution, then cultured in M9 medium supplemented with casmino acid and glucose (2 gm/L each), and incubating at 37 °C for 48hrs. Appearing growth in medium indicates positive results.

Cytochrome P450 production
Detection of cytochrome P450 (P450)-producing bacteria was done using an M9 medium containing a P450-inducer as the sole carbon source 2-ethoxyphenol as a carbon source. Bacterial isolates were cultured in tubes contain M9medium incubated at 37C for seven days 10. Quantification of cytochrome produced by bacteria was done using Modified microplate method 11.

Results:
Bacterial infection (Cystitis) in urine samples
From a total of 62 urine samples, only 32/62(51.6%) samples were positive for bacterial growth, including different species of bacteria. Three patients had co-infection (two bacterial species), so the total number of bacterial isolated was 35 isolates. The vast majority of bacteria isolated was Gram-negative bacteria 30/35(88.5%) while Gram-positive bacteria consisted 5/35 (11.5%).

Uropathic Escherichia coli is the most predominant bacteria isolated from patients with
TCC-BC, then *Stenotrophomonas maltophilia*, *Burkholderia cepacia*, *Pseudomonas* spp., *Enterococcus faecalis*, *Ochrobactrum anthropi*, *Acinetobacter* spp., *Sphingomonas paucimobilis*, *Bordetella bronchiseptica*, *Ralstonia mannitolilytica*, *Brevundimonas vesicularis* and *Kocuria rosea*, (Table 1).

**Table 1. Bacterial identification in urine samples from patients with TCC and patients with negative cystoscopy**

| Bacterial species              | Patient code | Number of patients |
|-------------------------------|--------------|--------------------|
| *E. coli*                     | 5, 25, 26, 7 | 7                  |
| *Stenotrophomonas maltophilia*| 6, 27, 38, 46, 50 | 6                  |
| *E. faecalis*                 | 30           | 4                  |
| *Burkholderia cepacia*        | 36, 42, 93, 98 | 4                  |
| *Pseudomonas* spp             | 19, 21, 22   | 3                  |
| *Ochrobactrum anthropi*       | 8, 39, 47    | 3                  |
| *Acinetobacter* spp           | 96, 72       | 2                  |
| *Sphingomonas* spp            | 23, 97       | 2                  |
| *Bordetella* spp              | 49           | 1                  |
| *Brevundimonas* vesicularis   | 44           | 1                  |
| *Ralstonia mannitolilytica*   | 92           | 1                  |
| *Kocuria rosea*               | 90           | 1                  |

It is important to explain presence of *E. coli* and *E. faecalis* in patients with TCC-BC in different stage since TCC-BC patients under high risk to infected with nosocomial bacteria even before surgery. While infection with opportunistic bacteria such as *S. maltophilia*, *P. aeruginosa*, *B. bronchiseptica*, *R. mannitolilytica*, *B. vesicularis* and *K. rosea* may be introduced to urinary tract through urinary catheter.

**Antibiotic Susceptibility**

Antibiotic susceptibility of different bacterial isolates from urine samples using VITEK 2 compact system are shown in Table 2.

**Table 2. Antibiotic susceptibility for *Escherichia coli***

| Antibiotic classes according to the mode of action | Code of bacteria | 5 | 25 | 26 | 31 | 35 | 40 | 94 |
|---------------------------------------------------|------------------|---|----|----|----|----|----|----|
| Cell wall inhibitor                                | R R R R R R R R  |
| Ticarcillin                                       | R R R R R R R R  |
| Ticarcillin/Clavulanic                             | R R R R R R R R  |
| Piperacillin                                       | R R R R R R R R  |
| Piperacillin/Tazobactam                            | R R R R R R R R  |
| Cefazidime                                         | R R R R R R R R  |
| Cefepime                                          | R R R R R R R R  |
| Imipenem                                          | I S S S S S S    |
| Azteronam                                         | R R R R R R R R  |
| Meropenem                                         | I S S S S S S    |
| Gentamycin                                        | R R R R R R R S  |
| Amikacin                                          | R S R I S S S    |
| Tobramycin                                        | R R R R R R R S  |
| Minocycline                                       | I R R I R S S    |
| DNA synthesis inhibitor                            | R R R R R R R S  |
| Ciprofloxacin                                     | R R R R R R R S  |
| Folic acid synthesis inhibitor phenotype           | R R R R R R R S  |
| Trimethoprim/Sulfamethoxazole                      | MDR ESBL*        |
| MDR ESBL - Polypeptide*                           | MDR ESBL         |
| MDR ESBL - Carbapenemase*                         | MDR ESBL         |
| MDR AmpC* - Cephalosporinase*                      | MDR ESBL         |
| MDR AmpC* - CARBA*                                | MDR ESBL         |
| MDR AmpC* - Porins*                               | MDR ESBL         |
| MDR AmpC* - CARBA*                                | MDR ESBL         |
| MDR AmpC* - Porins*                               | MDR ESBL         |

ESBL: extend spectrum beta-lactamase, MDR: multi drug-resistance, R: Resistance, +: positive, S: Sensitive, I: Intermediate.
Antibiotic susceptibility of *P. aeruginosa* and *P. fluorescens* shown in Table 3. *P. fluorescens* differ from *P. aeruginosa* in three antibiotics, aztreonam, minocycline and Trimethoprim/sulfamethoxazole.

### Table 3. Antibiotic susceptibility for *Pseudomonas* spp.

| Antibiotic classes according to the mode of action | Species | *P. aeruginosa* | *P. fluorescens* |
|---------------------------------------------------|---------|----------------|-----------------|
|                                                   | Code of bacteria | Antibiotic | 19 | 21 | 22 |
| Cell wall inhibitor                                | Ticarcillin     | R           | R  | S  |   |
|                                                   | Ticarcillin/Clavulanic | R    | R  | S  |   |
|                                                   | Piperacillin    | R           | R  | R  |   |
|                                                   | Piperacillin/Tazobactam | R    | R  | R  |   |
|                                                   | Ceftazidime    | R           | R  | R  | I  |
|                                                   | Cefepime       | R           | R  | R  | S  |
|                                                   | Imipenem       | R           | R  | R  | S  |
|                                                   | Aztreonam      | -           | -  | -  | R  |
|                                                   | Meropenem      | R           | R  | R  | S  |
|                                                   | Gentamycin     | R           | R  | R  | S  |
| Protein synthesis inhibitor                        | Amikacin       | R           | R  | R  | S  |
|                                                   | Tobramycin     | R           | R  | S  |   |
|                                                   | Minocycline    | -           | -  | S  |   |
| DNA synthesis inhibitor                            | Ciprofloxacin  | R           | R  | S  |   |
| Folic acid synthesis inhibitor                     | Trimethoprim/Sulfamethoxazole phenotype | Carbanpenemase, HL CASE++ R - CARBAPENEMS (imp) - ESBL |
|                                                   | Phenotype      | XDR            | MDR | XDR | XDR | XDR |

ESBL: extend spectrum beta lactamase, MDR: multi drug resistance, R: Resistance, + positive, S: Sensitive, I: Intermediate.

Only two antibiotics included in VITEK 2 compact system depend on updating for *S. maltophilia*, which was showed Resistance to Trimethoprim and Trimethoprim/sulfamethoxazole (83%) isolates, Table 4.

### Table 4. Antibiotic susceptibility for *Stenotrophomonas maltophilia*

| Antibiotic classes according to the mode of action | Antibiotic | Code of bacteria | 6 | 27 | 30 | 38 | 46 | 50 |
|---------------------------------------------------|------------|----------------|---|----|----|----|----|----|
| Inhibits folic acid synthesis                      | Trimethoprim | R            | R | R  | R  | R  | R  |   |
|                                                   | Trimethoprim/Sulfamethoxazole | R    | R  | S  | R  |   |   |   |
| phenotype                                          | XDR            | XDR | MDR | XDR | XDR | XDR | XDR |

XDR: extended drug resistance, MDR: multi drug resistance, R: Resistance, S: Sensitive.

*Bordetella bronchiseptica*, *Ralstonia* spp., *Sphingomonas paucimobilis* were showed variable patterns of antibiotic susceptibility, Tables 5 and 6.

### Table 5. Antibiotic susceptibility of *B. bronchiseptica, R. manntilolityca, B. vesicularis* and *O. anthropi*

| Antibiotic classes according to the mode of action | Code of bacteria | *B. bronchiseptica* | *R. manntilolityca* | *B. vesicularis* | *O. anthropi* |
|---------------------------------------------------|----------------|---------------------|--------------------|----------------|---------------|
|                                                   | Antibiotic | 49 | 92 | 44 | 8  | 39 | 47 |
| Cell wall inhibitor                                | Ticarcillin | I  | R  | R  | R  | R  | R  |
|                                                   | Ticarcillin/Clavulanic | I   | R  | R  | S  | R  | R  |
|                                                   | Piperacillin | R  | R  | I  | R  | R  | R  |
|                                                   | Piperacillin/Tazobactam | R   | R  | S  | R  | R  | R  |
|                                                   | Ceftazidime | R  | R  | R  | R  | R  | R  |
|                                                   | Cefepime    | R  | R  | I  | R  | R  | R  |
|                                                   | Imipenem    | S  | S  | S  | I  | R  | R  |
|                                                   | Aztreonam   | R  | R  | R  | R  | R  | R  |
|                                                   | Meropenem   | R  | I  | S  | I  | R  | R  |
|                                                   | Colistin    | I  | R  | R  | R  | R  | R  |
|                                                   | Gentamycin  | R  | R  | I  | R  | R  | R  |
| Protein synthesis inhibitor                        | Amikacin    | R  | R  | S  | R  | R  | R  |
|                                                   | Tobramycin  | R  | R  | R  | R  | R  | R  |
|                                                   | Minocycline | I  | S  | S  | I  | I  | I  |
|                                                   | Ciprofloxacin | R  | S  | R  | R  | R  | R  |
| DNA synthesis inhibitor                            | Trimethoprim/Sulfamethoxazole phenotype | MDR            | MDR | MDR | MDR | XDR | XDR |

MDR: multi drug-resistance, R: Resistance, S: Sensitive, I: Intermediate
Table 6. Antibiotic susceptibility for *Acinetobacter* spp., *Sphingomonas paucimobilis* and *B. cepacia*

| Antibiotic classes according to the mode of action | Code of bacteria | *S. paucimobilis* | *A. lwoffii* | *A. haemolyticus* | *B. cepacia* |
|--------------------------------------------------|----------------|-----------------|-----------|----------------|-------------|
| Antibiotic                                       |                |                 |           |                 |             |
| Cell wall inhibitor                              | Ticarcillin    | R               | S         | R               | R           |
|                                                  | Ticarcillin/Clavulanic | I               | R         | R               | R           |
|                                                  | Piperacillin   | R               | R         | R               | R           |
|                                                  | Piperacillin/Tazobactam | R         | R         | R               | R           |
|                                                  | Cefazidine     | R               | R         | R               | R           |
|                                                  | Ceftime        | R               | R         | I               | R           |
|                                                  | Imipenem       | R               | I         | R               | R           |
|                                                  | Aztreonam      | R               | R         | R               | R           |
|                                                  | Meropenem      | R               | R         | R               | R           |
|                                                  | Gentiacynin    | S               | R         | R               | R           |
|                                                  | Gentamycin     | R               | R         | R               | R           |
|                                                  | Tobramycine    | R               | R         | R               | R           |
| Inhibit DNA synthesis Inhibits Polypeptide synthesis | Ciprofloxacin | R               | S         | R               | R           |
|                                                  | Trimeprin/Sulfamethoxazole | D        | S         | R               | R           |

**ESBL:** extend spectrum beta-lactamase, **MDR:** multi drug-resistance, **R:** resistant, **S:** sensitive, **I:** intermediate.

**Table 7. Antibiotic Susceptibility for Enterococcus faecalis**

| Antibiotic classes according to the mode of action | Antibiotic | Code of bacteria | *Enterococcus faecalis* |
|--------------------------------------------------|------------|-----------------|------------------------|
|                                                  |            |                 | 23a | 31a | 40a | 43 |
| Cell wall inhibitor                              | Ampicillin | S               | S  | S  | S  | S  |
|                                                  | Cefazidine | R               | R  | R  | R  | R  |
|                                                  | Ceftime | R               | R  | R  | R  | R  |
|                                                  | Imipenem | R               | R  | R  | R  | R  |
|                                                  | Vancomycin, | R               | R  | R  | R  | R  |
|                                                  | Teicoplanin | R               | R  | R  | R  | R  |
| Inhibit protein synthesis                         | GN.H.L. S Gentamicin High Level (synergy) | S | S | S | S |
|                                                  | Streptomycin High Level (synergy) | R | R | R | S |
|                                                  | Amikacin | R               | R  | R  | R  | R  |
|                                                  | Tobramycine | R               | R  | R  | R  | R  |
|                                                  | Lineozolid | I               | S  | S  | S  | S  |
|                                                  | Tetracycline | R           | R  | R  | R  | R  |
|                                                  | Erythromycin | R          | R  | R  | R  | R  |
| Inhibit DNA synthesis                              | Ciprofloxacin | R       | R  | R  | R  | I  |
|                                                  | Levofoxacin | R               | R  | R  | R  | R  |

**MDR:** multi drug-resistance, **R:** resistant, **S:** sensitive, **I:** intermediate.

for *Kocuria rosea*. Antibiotic susceptibility patterns were shown in Tables 7 and 8. Gram-positive bacteria were included in four isolates of *Enterococcus faecalis* and one isolated...
Note: Bacteria code with a symbol (a) referred to two species of bacteria (dull infection) were isolated from the urine of the same patient, such as 23a was Enterococcus faecalis and 23 was Sphingomonas paucimobilis antibiotic pattern in the Table 6. Also, 31a and 40a was Enterococcus faecalis while 31, 40 were Escherichia coli antibiotic pattern in Table 2.

Table 8. Antibiotic Susceptibility for Kocuria rosea

| Antibiotic classes according to the mode of action | Code of bacteria | Kocuria rosea |
|---------------------------------------------------|------------------|---------------|
| Cell wall inhibitor                               | Antibiotic      |               |
| Ceftazidime                                       | R               |               |
| Cefepime                                          | R               |               |
| Imipenem                                          | R               |               |
| Vancomycin                                        | R               |               |
| Benzylpenicillin                                  | R               |               |
| Oxacillin                                         | R               |               |
| Meropenem                                         | R               |               |
| Teicoplanin                                       | R               |               |
| Protein Synthesis inhibitor                       | Gentamicin      | S             |
| Tetracycline                                      | R               |               |
| Tigecycline                                       | S               |               |
| Clindamycin                                       | R               |               |
| Erythromycin                                      | R               |               |
| Fusidic acid                                      | R               |               |
| DNA synthesis inhibitor                           | Ciprofloxacin   | S             |
| Moxifloxacin                                      | R               |               |
| RNA synthesis inhibitor                           | Rifampicin      | R             |
| Folic acid synthesis inhibitor                    | Trimethoprin/Sulfamethoxazole | S |
| phenotype                                         |                  |               |

- MDR: multi drug resistance, + positive, R: Resistance, S: Sensitive.

Identification of uro-pathogenic E.coli using pap E

Uro-pathogenic E.coli was first identified as E.coli using VITEK 2 Compact system, then at the molecular level using conventional PCR to detect the presence of papE and the results showed that 7/7 isolates had papE, Fig. 1.

Figure 1. Identification of pap E in Escherichia coli.

Lane 1,2,3,5,8, 11: isolates positive for pap E. Lane 4,6,7,10,12: isolates negative for pap E. Lane NTC: no template control. Lane L: DNA ladder molecular size control. Agarose concentration was 1.5%. Voltage used 45v and current used 100 Ampere for 1.30h.

Virulence Factors of Isolated Bacteria

Biofilm formation

The results of detection of biofilm formation of 35 isolates using TCP methods revealed that 17/35(49%) isolates were a strong producer for biofilm while 18/35 (51%) isolates were moderate producer for biofilm, Fig. 2.

Figure 2. Identification of Biofilm formation using ELISA readers: (TCP) method.

Siderophore production

Siderophore production ability of 35 isolates using M9 medium (Supplemented with vitamin B12 Casamino Acids and glucose) showed that 25/35
(71%) isolates were producer (growing on M9 medium) while 10/35 (29%) isolates were non-producer (no growth on M9 medium), Fig. 3.

**Figure 3. Identification of Siderophore production using M9 medium. Bacterial growth after incubation 37°C for 24hr.**

*Escherichia coli* (UPEC), *Stenotrophomonas maltophilia*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Brevundimonas vesicularis* and *Ralstonia mannitolilytica* isolates showed ability for siderophore production, while species of *Burkholderia cepacia*, *Sphingomonas paucimobilis* and *Ochrobactrum anthropi* isolates were showed variable ability for siderophore production, but species of *Pseudomonas fluorescence*, *Acinetobacter lwoffii*, *Acinetobacter haemolyticus*, *Bordetella bronchiseptica*, and *Kocuria rosea* isolates were not produced for siderophore.

**Cytochrome P450**

The ability of 35 isolates to grow on supplemented minimal medium for inducing cytochrome P450 expression protein was seen in 14/35 (40%) isolates as induced while (O.D reading => 0.2), while not induced in 21/35 (60%) isolates. *Sphingomonas paucimobilis*, *Ochrobactrum anthropi*, *Acinetobacter lwoffii* and *Acinetobacter haemolyticus* isolates were induced while *Stenotrophomonas maltophilia*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, and *Burkholderia cepacia* isolates revealed variable ability for inducing. However, *Escherichia coli* (UPEC) *Brevundimonas vesicularis*, *Ralstonia mannitolilytica* *Bordetella bronchiseptica* and *Kocuria rosea* isolates showed no ability for inducing, Fig. 4.

**Figure 4. Turbidity in cytochrome induced medium after one week (incubation at 37°C).**

The range of O.D reading in ELISA reader for all isolates either producer or non-producer of cytochrome P450, in addition to negative control which contains only M9 medium, Fig. 5.

**Figure 5. Diagram explains the ability of bacteria to produce cytochrome P450 proteins (O.D reading).**

**Discussion:**

**Bacterial infection (Cystitis)**

The infection of *S.maltophilia* and *P.aeruginosa* in patients with a negative cystoscopy may be related to those patients’ bloody urine and the nature of these bacteria, especially...
S. maltothophilia which need iron as essential nutrients for bacterial survival. Iron was found to play a crucial role in the regulation of numerous virulence factors. A study done in Egypt in 2015 found that, in 20 patients with TCC-BC, only 15 of them had urinary tract infection, and the most predominant organism isolated was Escherichia coli. A study in the United States at (2013) referred to that endogenous bacteria, including cystitis, caused by bladder bacteria (bladder pathogens) and some intestinal opportunistic Pseudomonas aeruginosa, metabolically activate the bladder procarcinogens, while urinary bladder infection by E. coli plays a significant additive and synergistic roles during bladder carcinogenesis. A study in China in 2019 from a total of 24 urine sample from patients with bladder cancer revealed the abundance of common core bacteria is significantly higher in bladder cancer urine samples, especially Acinetobacter which is much higher in bladder cancer urine samples because of bacterial ability for biofilm formation, adhesion and invasion of epithelial cells.

A hospital-based comparative cross-sectional study in Ethiopia in 2019 included 240 patients with any type of cancer; they found that E. coli (32.1%) was the most common bacteria isolated followed by Klebsiella species (25.0%), Staphylococcus aureus (21.4%), Enterococcus species (10.7%), Serratia species (7.1%), and Enterobacter aerogenes(3.6%) in the urine of patients with any type of cancer. It is essential to focus on urinary tract infection (Inflammation or Chronic Inflammation) since that chronic inflammation induced by biological factors associated with increased risk of human cancer at various sites due to Inflammation activates a variety of inflammatory cells, which induce and activate several oxidant-generating, by which these enzymes produce high concentrations of diverse free radicals and oxidants that react with each other to generate other more potent reactive oxygen and nitrogen species which can damage DNA, RNA, lipids, and proteins thus increased mutations and altered functions of enzymes and proteins (e.g., activation of oncogene-products and inhibition of tumor-suppressor proteins).

Antibiotic Susceptibility

This study percentage of multi drug resistance bacteria MDR (62.8%) while extended drug resistance was XDR (28.5%). In Zakho city in Iraq 2016, a study included 106 UPEC isolates, resistance was (100%) to penicillin, ampicillin, and aztreonam. While (100%) were sensitive to imipenem and meropenem. Another study in Iraq in Erbil 2018 included 25 isolates of UPEC, resistance percentage between 28 to 96% to amikacin, amoxicillin, ampicillin, chloramphenicol, ciprofloxacin, erythromycin, nalidixic acid, penicillin, tetracycline, and trimethoprim. A study in Iran in 2018 included 60 strains of uropathic E.coli was investigated antibiotic susceptibility using the Kirby Bauer disk diffusion method. They were found resistant to cefepime (100%) and cephalothin (74%) and while sensitive to imipenem (100%), vancomycin (100%), and doxycycline (100%). A study in Mexico in 2014 included 119 isolates of Stenotrophomonas maltophilia collected between 2006 to 2013, with a resistance rate above 75% for imipenem, meropenem, ampicillin, aztreonam, gentamicin, and tobramycin, while resistance to trimethoprim-sulfamethoxazole was 32.8%. While in Turkey, a study published in 2016 included 118 isolates of Stenotrophomonas maltophilia collected in a period extended from 2006 to 2012, they found that the resistance rate was 7.6% Levofloxacin. 18.2% chloramphenicol, 20.3% trimethoprim-sulfamethoxazole and 72% ceftazidime.

In 2019 a retrospective cohort study in Hungary extended from 2008 to 2017 included 579 isolates of Stenotrophomonas maltophilia, concluded 5.35% of isolates were multidrug-resistant (MDR) while 5.87% were extensively drug-resistant (XDR), that is, in addition to SMX/TMP, they were resistant to amikacin, colistin, Levofloxacin, and tigecycline. In Nigeria 2018, a study included five isolated Pseudomonas aeruginosa, which were Resistance to Ampicillin and Amoxicillin/Clavulanic acid. In Prague, a study extended from 2011 to 2019 included 6897 isolates from total P. aeruginosa form 180 (7.3%) of isolates, which were resistant to ofloxacin and sensitive to colistin.

A study in Duhok in Iraq in 2018 included 371 isolates from a total of 276 (74.4%) E.coli, 12 (2.8) P.aeruginosa, and 9 (2.4) Acinetobacter sp. Which were shows a varies pattern of antibiotic susceptibility also Acinetobacter sp showed resistance (100%) to Aztreonam, Augmentin and Nitrofurantoin while P.aeruginosa resistance (100%) to Augmentin. A study in India in 2018 included 67 isolates of Acinetobacter sp were tested for sensitivity pattern using disk diffusion methods, which were 80.3% of isolates was multi drug resistance but (100%) sensitive to colistin. Case report study in India in 2017 included isolate of Ochrobactrum anthropi from patients with septicemia; antibiotic susceptibility was done using VITEK® 2 Compact system, which was multidrug-
resistance, resistance to a wide range of antibiotics-ceftazidime, cefoperazone, cefepime, chloramphenicol, sulbactam, piperacillin/tazobactam, ciprofloxacin, imipenem, and meropenem while was susceptible to amikacin, tigecycline, cefepime–tazobactam, colistin, cotrimoxazole. A study in Jordon 2017 included four isolates of B.cepacia complex isolates from the urine; antibiotic susceptibility was done using disk diffusion methods, which were resistant to lincomycin, nalidixic acid, oxacillin and penicillin G and sensitive to ceftazidime, ciprofloxacin, gentamicin, imipenem, and Levofloxacin. One year prospective study in India 2018 included 43 isolates of B.cepacia complex isolates from blood and sputum, antibiotic susceptibility was done using VITEK 2 Compact system, showed Maximum Resistance with β-lactamase inhibitor drugs (83.7%) 33. Case report study 2017 in Malaysia isolates Ralstonia mannitolilytica from the blood of 65 years female with underlying hypertension, diabetes mellitus and ischaemic heart disease as well as received regular renal dialysis culture showed sensitivity to ceftazidime and piperacillin/tazobactam while resistant to amikacin, gentamicin, meropenem and polymyxin 32.

Another case report study (2019) in Italy studying Antibiotic susceptibility of Ralstonia mannitolilytica isolated from the blood of 46 years female with underlying diseases using the broth micro dilution method which resisted to a wide range of antibiotic including Amikacin, Aztreonam, cefepime, Ceftazidime, Ertapenem, gentamycin, imipenem, and meropenem 33. While in China (2019) antibiotic susceptibility was studied using the VITEK 2 Compact system on two isolates of Ralstonia mannitolilytica isolated from blood indicated resistance to aminoglycosides, β-lactams, and polymyxin B 34. Another case study in India 2014 included isolate of Brevundimonas vesicularis antibiotic susceptibility was done using disc diffusion methods, which was susceptible to piperacillin-tazobactam, minocycline, and cotrimoxazole, while resisting to amikacin, gentamicin, tobramycin, netilmicin, amoxicillin, amoxicillin-clavulanic acid, cefoxitin, cefotaxime, cefoperazone, ceftazidime, cefoperazone-sulbactam, imipenem, meropenem, ertapenem, aztreonam, norfloxacin, Levofloxacin and colistin 35.

A study in Kalkata in 2015 included 115 isolates of Enterococcus faecalis, which were resistant to ciprofloxacin (86.1%), amikacin (77.4%), cotrimoxazole (78.3%), and imipenem (52.2%) 36. Case report study in China in 2020 included E. faecalis isolated from the urine of patients with underlying diseases, the drug of choice was Linezolid 37. Case report study in India 2016 included Kocuria species isolated from urine, which was Resist to ampicillin, oxacillin, cefoxitin, ciprofloxacin, norfloxacin, nalidixic acid, piperacillin-tazobactam, amoxicillin-clavulanic acid, ceftriaxone, cefotaxime, cefepime and ceftazidime, while sensitive to vancomycin, linezolid, imipenem, amikacin, ofloxacin, trimethopr-im-sulfamethoxazole, clindamycin, erythromycin, and tetracycline 38.

Identification of uropathogenic E.coli using papE gene

In this study, uropathogenic Escherichia coli (UPEC) is the most predominant bacteria isolated from bladder cancer patients. A study in Egypt in 2015 referred to that E. coli is the most common uropathogenic bacteria, which infects bladder cancer patients. Surface virulence factors (adhesins) are significance virulence factors of UPEC as the primary attachment factor, P fimbriae are associated with pyelonephritis and are encoded by pap genes(Pyelonephritis-Associated Pili), allowing them to colonize host mucosal surfaces and invade the normally sterile urinary tract 39. A study in Al-Kufa, Iraq (2015) investigated the severity of urinary tract infections in 48 patients with TCC and 20 patients with non-TCC as a negative control group. They obtained bacterial growth from 15 cultured urine samples. Among them, 41.67% were Gram-positive bacteria, and 27.78% was Gram-negative bacteria 40. A prospective descriptive (cross-sectional) Iraqi study in 2020 included 170 specimens (100 urine and 70 stool specimens) screened for papE gene using conventional PCR. They indicated that (29/100) isolates were identified as UPEC 41.

In Iran, Rahdar et al. (2015) referred to that from 100 isolates of E.coli isolated from the urine of patients with UTI, only 57% was harbor papE detected using PCR 42. In Egypt, a study in 2019 included 173 isolates of UPEC and diarrheagenicE.coli(DEC) investigated for phylogenetic typing and urovirulence genes using PCR, results 16.5% of UPEC was harbor papE but not present in DEC 43.

Virulence Factors of Isolated Bacteria Biofilm formation

In this study, all isolates were produced biofilm either moderate 17/35 (51%) or strong producer 17/35 (49%). The quantification test of biofilm was proved to be useful in detecting biofilm production by the clinical isolates (44). Urinary tract infections significantly associated with microbial biofilms, developed on catheters which conclude a high percentage of all nosocomial infections and are the most prevalent source of
Gram-negative bacteremia in hospitalized patients. Biofilm formation is also considered a virulence determinant responsible for the long-lasting persistence of bacteria in the genitourinary tract. Escherichia coli (UPEC) form biofilms on urinary catheters, as well as within bladder epithelial cells, which protects UPEC from environmental conditions, antimicrobial therapy, ultraviolet radiation, oxidizing biocides, and host immune defenses. Iranian study in 2018 included 100 isolates of UPEC was screened ability for producing biofilm using microtiter plate methods (TCP) indicated 36/100 was strong producer, 48/100 was moderate producer, and 10/100 was the weak producer. Another study in India in 2019 included 100 isolates of E. coli isolated from patients suffering from UTI, was studied the ability to produce biofilm their results indicated 69% of isolates were producers of biofilm. Hungarian study in 2020 on 250 isolates of E. coli from patients with UTI screened ability for producing biofilm using crystal violet tube- adherence method their results indicated that 119 (47.6%) were positive for biofilm formation. A study in Mexico in 2014 included 119 isolates of Stenotrophomonas maltophilia collected between 2006 to 2013, indicated that All S. maltophilia isolated were able to produce biofilms. Strains were classified as strong biofilm producers (13.4%, 16/119), moderate, (38.7%, 46/119), or weak (47.9%, 57/119).

Pseudomonas aeruginosa produce biofilm is an essential mechanism for survival, and its relationship with antimicrobial-resistance represents a challenge for patient therapeutics, especially in nosocomial infections of immune-compromised patients. A study in Brazil in 2018 compromised 40 clinical isolates of P. aeruginosa has studied ability to produce biofilm using TCP method their results indicate 77.5% of isolates were biofilm producer. A study in Belgium in 2014 in six isolates of Burkholderia sp. studied their ability to produce biofilm using TCP, indicated all isolates were able to produce biofilm but in different percentage. Egyptian study in 2017 included 90 clinical isolates of Enterococcus faecalis studied their ability to produce biofilm using two methods Congo-Red agar (CRA) biofilm assay and TCP method. In (CRA) five potent biofilm-producing isolates 81 isolates ranged between moderate and weak, and 4 non-biofilm-producing isolates while in TCP methods only 5/90 (5.5%) were classified as strong biofilm-formers; 38/90 isolates (42%) were moderate; 43/90 were weak biofilm-formers (48%); and 4/90 (4.5%) could not form biofilm. A study in china 2018 included 113 isolates of E. faecalis from urine of patients with UTI, studied the ability to produce biofilm using TCP methods, indicated that (59.7)% as a strong biofilm producer while (30.6)% as non-biofilm producer.

**Siderophore production**

In the present study, 25/35 (71%) isolates were producer while 10/35 (29%) isolates were non producer. A study in India in 2017 included 200 isolates of UPEC isolated from patients with UTI, screened for siderophore production using Chrome azurol assay (CAZ) noticed that (95%) of isolates were siderophore production indicated that siderophores or Iron acquisition constitute a significance virulence factor requisite for Uropathogenic E. coli in the pathogenesis of UTI. Another study in al-Kufa in Iraq in 2017 included 50 isolates of E. coli from different infections, screened for virulence factors including siderophore production using M9 medium supplemented with 2,2'-dipyridyl, their results indicated (100%) of isolates were siderophore producer. A study in Argentina in 2012 included 31 clinical isolates of S. maltophilia screened for siderophore production using (CAZ) assay indicated that all isolated(100%) were siderophore production.

**Cytochrome P450**

In the present study, the inducing of cytochrome P450 expression protein was seen in (14/35) 40% isolates as induced, while not induced in (21/35) 60% isolates. Many types of research indicated that microorganisms such as Bacteria were shown to express cytochrome CYP-like genes (these genes in microbial organisms differ extensively even between species of the same genus) even though individual organisms having no CYP genes present (e.g., Escherichia coli), the considerable metabolic activity of the microbe is associated to its abundant collect of CYP enzymes. This reason could explain the failure to induce (8) isolates of UPEC to express cytochrome P450. It was also reported that Bacterial cytochrome P450s were characterized in their high expression level in many microorganisms.

Microbial P450s have diverse catalytic functions. For example, in Sphingomonas paucimobilis had fatty acid α-hydroxylase (H2O2 dependent peroxygenase), and in Pseudomonas sp function as α-terpineol hydroxylase activity. Besides Microbial P450s have roles in the degradation of toxic compounds. It is crucial to study microbes' ability to express cytochrome P450 proteins (specifically quantity) in the cell wall because Pseudomonas aeruginosa would metabolically activate the bladder procarcinogens, which is achieved by the presence of cytochrome P450.
Conclusion:

Patients with TCC-BC or negative cystoscopy who had a urinary catheter or immune-compromised were at high risk of infecting with nosocomial or opportunistic pathogens, which could develop resistance antibiotic the central problem in treating these patients before undergoing to chemotherapy or immune cancer therapy.

Authors’ declaration:
- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are mine ours. Besides, the Figures and images, which are not mine ours, have been given the permission for re-publication attached with the manuscript.
- The author has signed an animal welfare statement.
- Authors sign on ethical consideration’s approval
- Ethical Clearance: The project was approved by the local ethical committee in Al-Nahrain University

Authors’ contributions statement:
Sura Mouaid Abbas was contributed to sample collection samples and implementation of the research Maysaa Abdul Razzaq Dhahi was contributed to the design of the research, to the analysis of the results and to the writing of the manuscript. All authors discussed the results and contributed to the final manuscript

References:
1. Salvatore S, Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, et al. Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol. 2011 Jun;156(2):131-6
2. Vermeulen SH, Hanum N, Grotenhuis A J, Castan G, Vinyals O, Heijden AG, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015 Feb;112(3):594-600.
3. Robino L, Gonzalez MJ, Radio G, Gomez V, Scavone P. Fosfomycin trometamol activity on biofilm and intracellular bacterial communities produced by Uropathogenic E. coli isolated from patients with Urinary tract infection. IJID.2018Aug;73(142): 3–398.
4. Delcaru C, Alexandru I, Podgoreanu P, Grosu M, Elisabeth S, Mariana C, et al. Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating strategies. Pathogens. 2016 Nov;5(4):65.
5. Ainsworth C. Microbiome: a bag of surprises. Nature. 2017 Nov;551(7679):S40-1.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 2017.
7. Johnson JR, Stell AL. Extended Virulence Genotypes of Escherichia coli Strains from Patients with Urosepsis in Relation to Phyllogy and Host Compromise. J Infect Dis. 2000 Jan;181(1):261-72.
8. Titik N. Current in vitro assay to determine bacterial biofilm formation of clinical isolates. J Med Sci.2014 Sep; 46(3): 142-152
9. Karen E, Roger B. Media Preparation and Bacteriological Tools. New York. Wiley:2002cited 01 August 2002]1.0.1- A1.K.26p.https://doi.org/10.1002/0471142727.mb0101s59
10. Ikatsu H, Kino Y, Kawahra N, Adachi M, Miyoshi S, Tomochika K, et al. Isolation and Characterization of Cytochrome P450-Producing Bacteria from Various Environments. Biocontrol Sci. 2000 Apr ;5(2): 111-116.
11. Naveen KA, Maya V. Modified microplate method for rapid and efficient estimation of siderophore produced by bacteria. 3 Biotechn. 2017 Dec;7(6):381.
12. Kalidasan V, Adleen A, Narcisse J, Suresh K, Rukman AH, Vasantha KN. Will Go to War for Iron: Stenotrophomonas maltophilia Strategy. Molecules. 2018 Aug;23(8):2048.
13. Ahmed E, Mohamed A, Romaila R, Mahmoud M Z, Bede A. Effect of pathogenic bacteria on reliability of CK-19, CK-20 and UPII as bladder cancer genetic markers: A molecular biology study, Egypt. j. basic appl. sci. 2015 Sep; 2(3): 176-182.
14. Adris P, Estraño C, Chung KT. The metabolic activation of 2-aminofluroine, 4-aminobiphenyl, and benzidine by cytochrome P-450-107S1 of Pseudomonas aeruginosa. Toxicol In Vitro. 2000 Dec;21(8):1663-71.
15. El-Mosalamy H, Salman TM, Ashmawey AM, Osama N. Role of chronic E. coli infection in the process of bladder canceran experimental study. Infect Agent Cancer. 2012 Aug;7(1):19.
16. Guoqin M, Limei C, Ran L, Quan L, Haoran Z, Yingfei M. Common Core Bacterial Biomarkers of Bladder Cancer Based on Multiple Datasets. BioMed Research International. 2019 May; 8:1-8.
17. Abiye T, Worku F, Gizeaddis B, Baye G. Prevalence of Asymptomatic Bacteriuria and Antibiotic Susceptibility Patterns of Bacterial Isolates among Cancer Patients and Healthy Blood Donors at the University of Gondar Specialized Hospital. Hindawi Int. J. Microbiol. 2020 Mar;9
18. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys. 2003 Sep;417(1):3-11.

19. Polse RF, Yousif SY, Assafi MS. Prevalence and antimicrobial susceptibility patterns of uropathogenic E. coli among people in Zakho, Iraq. Int J Res Med Sci. 2016 Apr; 4(4):1219-1223.

20. Mohammad K, Ahmed Z, Mohammed B, Saeed R. Determination the site of antibiotic resistance genes in Escherichia coli isolated From Urinary Tract Infection. KJA R. 2018 Oct; 3(2): 6-12.

21. Raeispour M, Ranjbar R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains. Antimicrob Resist Infect Control. 2018 Oct ;7:118.

22. Flores-Treviño S, Gutiérrez-Fernan JL, Morfín-Otero R, Rodríguez-Noriega E, Estrada-Rivadeneyra D, Rivas-Morales C, et al. Stenotrophomonas maltophilia in Mexico: antimicrobial resistance, biofilm formation and clonal diversity. J Med Microbiol. 2014 Nov; 63(11):1524-1530.

23. Çıkman A, Parlak M, Bayram Y, Gündücioğlu H, Berkaş M. Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens. Afri Health Sci. 2016 Mar;16(1): 149-152.

24. Ma’rio’G, Edi U. Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot. Health Serv Res Manag Epidemiol. 2019 Aug; 6:2333392819870774.

25. Ezenobi NO, Ogbu HI, Onosigho I. Antimicrobial susceptibility pattern of urinary isolates from outpatients suspected for urinary tract infection. GSC Biol. Pharm.Sci. 2018 Nov; 5(3): 01-11.

26. Jan H, Pavel C, Roman Z. Current Antibiotic Resistance Trends of Uropathogens in Central Europe: Survey from a Tertiary Hospital Urology Department 2011–2019. Antibiotics. 2020 Jan; 9(9):630.

27. Nawfal RH, Shameran D, Khoshi S, Mahde SA. Urinary Tract Infections and Antibiotic Sensitivity Patterns Among Women Referred to Azadi Teaching Hospital, Duhok, Iraq. vicenna J Clin Microbiol Infect. 2018 Dec; 5(2): 27-30.

28. Tewari R, Chopra D, Wazahat R, Dhingra S, Dudeja M. Antimicrobial Susceptibility Patterns of an Emerging Multidrug Resistant Nosocomial Pathogen: Acinetobacter baumannii. J Med Sci. 2018 May; 25(3):129-134

29. Neha R, Purva M. Ochrobactrum anthropi: An emerging pathogen causing meningitis with sepsis in a neurotrauma patient. J Infect Dev Ctries. 2017 Sep;11(9):733-735.

30. Nimri L, Sulaiman M, Hani OB. Community-acquired urinary tract infections caused by Burkholderia cepacia complex in patients with no underlying risk factor. JMM Case Rep. 2017 Jan ;4(1): 005081

31. Shukla R, Bilolikar AK, Udayasri B, Pragy R. Antibiotic susceptibility pattern of Burkholderia cepacia complex from various clinical samples in a tertiary care center: A one-year prospective study. J Med Sci Res. 2018 Jan; 6(1):1-5.

32. Lim CTS, Lee SE. A rare case of Ralstonia mannitolilfictica infection in an end stage renal patient on maintenance dialysis during municipal water contamination. Pak J Med Sci. 2017 Aug;33(4):1047-1049.

33. Monica B, Carolina V, Giammarchio R, Anna SN, Francesco A, Emanuela G, et al. A case of persistent bacteraemia by Ralstonia mannitolilfictica and Ralstonia pickettii in an intensive care unit. Infect Drug Resist. 2019 Aug;12: 2391-2395.

34. Qingqing F, Yu F, Ping F, Xiaohui W, Zhiyong Z. Nosocomial bloodstream infection and the emerging carbapenem-resistant pathogen Ralstonia insidiosa. BMC Infect Dis. 2019 Apr; 19:334.

35. Gupta PK, Appannavar SB, Kaur H, Gupta V, Mohan B, Taneja N. Hospital acquired urinary tract infection by multidrug-resistant Brevundimonas vesicularis. Indian J Pathol Microbiol. 2014 Sep;57(3):486-8

36. Mohua B, Shiv SC, Khey A, Sanjeev D, Chinmoy G, Banya C, et al. Enterococcal Urinary Taract Infection: An Emerging Threat. J. Evol. Med. Dent. Sci. 2015 Mar; 4(17).

37. Manshi L, Fuhuo Y, Yihan L, Weifeng H. Identification of Enterococcus faecalis in a patient with urinary-tract infection based on metagenomic next-generation sequencing: a case report. BMC Infect Dis. 2020 Jul; (20):467

38. Ramana VK. A case of urinary tract infection caused by Kocuria species and identified by conventional methods. Perspect Clin Res. 2016 Aug; 7(4): 005081

39. Wafaa A, Somaya M, Abeer A, Hasnaa S. Detection of Some Virulence Factors and Pyelonephritis–Associated Pilius (pap) Encoding Operon Gene in Uropathogenic Escherichia coli. Egypt J Med Microbiol. 2015 Jul;24 (3):37-43

40. Zina MA. Immunonohistochemical Detection of Gram-Positive Bacterial LTA associated with Urinary Tract Infection among Urinary Bladder Cancer patients. J. Nat. Sci. Res. 2015 Sep; 20(5):19-25

41. Noor JO, Maysaa ARD. The Role of Mutation and Gene Expression Level of marRAB operon in Multi Antibiotic Resistance uropathic Escherichia coli and
0157:H7 isolates from patients in Baghdad. J. Pharm. Sci. & Res. 2020Apr; 12(3): 365-374

42. Masoud R, Ahmad R, Hamid RM, Mehdi RG. Detection of pap, sfa, afa, foc, and fim Adhesin-Encoding Operons in Uropathogenic Escherichia coli Isolates Collected from Patients with Urinary Tract Infection. Jundishapur J Microbiol. 2015 Aug; 8(8).

43. Khairy RM, Mohamed ES, Abdel Ghany HM, Abdelrahim SS. Phylogenic classification and virulence genes profiles of uropathogenic E. coli and diarrheogenic E. coli strains isolated from community acquired infections. PLoS ONE.2019Sep; 14(9).

44. Lima JLC, Alves LR, Paz JNP, Rabelo MA, Maciel MAV, Morais MMC. Analysis of biofilm production by clinical isolates of Pseudomonas aeruginosa from patients with ventilator-associated pneumonia. Rev Bras Ter Intensiva.2017 Sep;29(3):310-316.

45. Roshi AMA, Venkitanarayanan K. Role of Bacterial Biofilms in Catheter-Associated Urinary Tract Infections (CAUTI) and Strategies for Their Control. Vienna. Thomas Nelius: 2013[cited July 10th 2013] 184p.https://www.intechopen.com/books/recent-advances-in-the-field-of-urinary-tract-infections/role-of-bacterial-biofilms-in-catheter-associated-urinary-tract-infections-cauti-and-strategies-for-

46. Cristina D, Ionela A, Paulina P, Mirela G, Elisabeth S, Mariana CC, et al. Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating strategies. Pathogens. 2016 Dec; 5(4):65.

47. Eberly AR, Floyd KA, Beebout C J, Colling S J, Fitzgerald M J, Stratton CW, et al. Biofilm Formation by Uropathogenic Escherichia coli Is Favoured under Oxygen Conditions That Mimic the Bladder Environment. Int J Mol Sci. 2017 Sep;18(10):2077

48. Hojjatolah Z, Ali S. Biofilm formation in uropathogenic Escherichia coli: association with adhesion factor genes. Turk J Med Sci. 2018Feb; 48(1): 162-167.

49. Karigoudar RM, Karigoudar MH, Wavare SM, Mangalgi SS. Detection of biofilm among uropathogenic Escherichia coli and its correlation with antibiotic resistance pattern. J Lab Physicians. 2019 Jan; 11(1):17-22.

50. Payam B, Edit U, Máríó G. Association between Biofilm-Production and Antibiotic Resistance in Uropathogenic Escherichia coli (UPEC): An In Vitro Study. Diseases. 2020 Jun; 8(2):17.

51. Maurice NM, Bedi B, Sadikot RT. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections. Am J Respir Cell Mol Biol. 2018 Apr;58(4):428-439

52. Jaitlon LCL, Paula RL AJ, João PBN, Maria AVM, Marcia MCM. Biofilm production by clinical isolates of Pseudomonas aeruginosa and structural changes in LasR protein of isolates non biofilm-producing. Braz J Infect Dis.2018 Apr;22(2):129-136

53. AnneS, Messiah H, Nelis'Tom C. Investigating the role of matrix components in protection of Burkholderia cepacia complex biofilms against tobramycin. J. Cyst. Fibros. 2014Jan; 13(1): 56–62.

54. Yomna AH, Heba MA, Tamer ME, Aymen SY, Ramy KA. Biofilm formation in enterococci: genotype-phenotype correlations and inhibition by vancomycin. Sci Rep. 2017 Jul 18;7(1):5733

55. Zheng JX, Bai B, Lin ZW, Pu ZY, Yao WM, Chen Z, et al. Characterization of biofilm formation by Enterococcus faecalis isolates derived from urinary tract infections in China. J Med Microbiol. 2018 Jan;67(1):60-67

56. Mehvish S, Betty D. Detection of Siderophore production in Uropathogenic Escherichia.coli in patients with Type 2 Diabetes Mellitus. IP Int J Med Microbiol Trop Dis. 2017 Dec;3(4):176-177

57. Ahmed AJ, Qassim MH. Phenotypic and molecular characterization of some virulence factors in multidrug resistance Escherichia coli isolated from different clinical infections in Iraq. Am. J. Biochem. Mol. Biol.2017 Apr; 7(2): 65-78

58. García C, Passerini B, Alcaraz E, Vay C, Franco M. Siderophores of Stenotrophomonas maltophilia: detection and determination of their chemical nature. Rev. Argent. Microbiol. 2012; 44: 150-154.

59. Stavropoulou E, Pircalabioru GG, Bezirtzoglou E. The Role of Cytochromes P450 in Infection. Front. Cell. Infect. Microbiol. 2018Nov; 3(11) 89.

60. Xiaodong Z, Yaqin P, Jing Z, Qian L, Xiaojuan Y, Carlos G, et al. Bacterial cytochrome P450-catalyzed regionoand stereoselective steroid hydroxylation enabled by directed evolution and rational design. Bioresour. Bioprocess. 2020Dec; 7(2):1-18

61. Halasz A, Manno D, Perreault NN, Sabbadin F, Bruce NC, Hawai J. Biodegradation of RDX nitroso products MXN and TNX by cytochrome P450 XpIA. Environ Sci Technol. 2012Jul; 46(13):7245–7251
دراسة بعض عوامل الضراوة ومقاومة المضادات للكتيريا المعزولة من إدرار المرضى المصابين بسرطان المثانة

شرق مؤيد عباس
ميساء عبد الرزاق ضاحي
فرع الاحياء المجهري، كلية الطب، جامعة النهرين، بغداد، العراق

الخلاصة:
التهاب المجاري البولية تعني وجود المكروبات الممرضة بالاحليل أو المثانة. أهم الأسباب لحدوث الأصابات المتكررة هو تخدش المجرى البول نتيجة استعمال القسطرة البولية أو الأشخاص المكبوحين مناعيا. الدراسة الحالية ركزت على عزل وتشخيص المكروبات التي تتسبب في الالتهاب المجاري البولية، ودراسة المقاومة الحيوية. وبعض من عوامل الضراوة في الأشخاص المصابة بسرطان المثانة. تشمل دراسة المقاومة المرضية في البكتريا المعزولة. 

تم جمع 62 عينة ادرار (50 مرضي سرطان المثانة و12 مريض تنظير المثانة سلبي) فقط 32 عينة كانت موجبة لوجود البكتريا وكانت النسبة الاعلى بالاصابة هي Escherichia coli (E. coli). نسبة العزلات المقاومة للمضادات الحيوية كانت (62.8%) MDR بينما كانت (28.5%) XDR. وكانت كل العزلات لها القابلية على إنتاج الفضلات الحيوية، كما أظهرت النتائج أن 35% من العزلات لديها انتاج البكتيريا الحيوية. كانت نسبة البكتريا المقاومة للمضادات الحيوية (71%) من النوع UPEC. وتعتبر هذه النتائج مهمة في علاج هذه الفئة من المرضى قبل اعطاء العلاج الكيميائي.

الكلمات المفتاحية: حساسية للمضادات، سايتوكروم P450، إنتاج السيتروفور، سرطان المثانة، عوامل الضراوة.